Alcon AG（ALC）のニュースとイベントALCAlcon AG

Alcon Acquires Neurotech Pharmaceuticals for $550 Million

Alcon announced it has acquired Neurotech Pharmaceuticals, a company focused on developing innovative cell therapies for chronic and neurodegenerative eye diseases. This acquisition expands Alcon's retina portfolio with ENCELTO, or revakinagene taroretcel-lwey, the first and only U.S. FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type 2, or MacTel, a rare, progressive retinal disease that leads to irreversible central vision loss that has historically had no approved treatment options. ENCELTO is an encapsulated cell therapy that is intended for surgical intravitreal implantation. The FDA granted ENCELTO priority review status and Orphan Drug designation and approved ENCELTO under a Biologics License Application, or BLA, in March 2025. It currently is available in the U.S. only. It is estimated that there are approximately 25,000 diagnosed MacTel patients in the U.S. with 2,000-3,000 patients newly diagnosed annually.1-3, Until ENCELTO, there have been no FDA-approved treatments for MacTel patients. As part of the acquisition, Alcon paid $550M to acquire Neurotech Pharmaceuticals. Alcon may be required to make additional contingent payments, including upon the achievement of commercial milestones. Alcon expects the transaction to be modestly accretive to net sales growth and slightly dilutive to core diluted eps in 2027, and accretive thereafter. Goldman Sachs & Co, served as financial advisor to Alcon and Gibson, Dunn & Crutcher served as legal advisor to Alcon. J.P. Morgan Securities served as lead financial advisor to Neurotech, and Cravath Swaine & Moore served as lead legal advisor to Neurotech. Other advisors to Neurotech included Rothschild & Co, Ropes & Gray, Fenwick & West and Elrifi Law.

Alcon Receives FDA Approval for Brytly Eye Drops

Alcon announced that the U.S. FDA has approved Brytly Redness Reliever Eye Drops. With one drop, Brytly works in just one minute to significantly reduce redness and delivers up to 12 hours of whiter, brighter-looking eyes. Additionally, Brytly lasts up to 50% longer than Lumify. Brytly is expected to be available at major retailers nationwide and online in the coming months, and in additional markets in the future.

Alcon Launches UNITY M Surgical Microscope

Alcon announced the initial commercial launch of UNITY M, an Alcon brand premium surgical microscope that delivers precise control to ophthalmic surgeons, in select markets including the U.S. and Japan followed by Europe. UNITY M will be featured at the upcoming Congress of the European Society of Cataract and Refractive Surgeons. The microscope is the latest addition to Alcon's UNITY platform, combining advanced optics, novel illumination, improved ergonomics, and intuitive usability in a modular design that enables practice-specific customization and future scalability